VORSCHAU
Frühere Meldungen
PRESSETERMINE
AKTUELLES PRESSEFOTO
IR Nachrichten
17.05.2024 18:06
Wiener Privatbank SE
17.05.2024 16:55
Schumag Aktiengesellschaft
17.05.2024 16:00
Medigene AG
EUROPA NACHRICHTEN
ADHOC
Mi, 15.03.2023 16:45
pta20230315026
Business news for the stock market
Medigene AG: Medigene AG to report full year 2022 financial results on March 29, 2023Planegg/Martinsried (pta026/15.03.2023/16:45) - Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will report financial results and provide a corporate update for the fiscal year ended December 31, 2022 on Wednesday, March 29, 2023. Following the release of the full year 2022 financial results on Medigene's website, the company will host a conference call that same day at 3 p.m. CET (9 a.m. ET). Full details for the conference call and webcast are as follows:
Please dial in 10 minutes ahead of time to ensure a timely start of the conference call. Following the call, an archived webcast will be accessible on the Investors & Media section of the Medigene website: https://www.medigene.com/investors-media/reports-presentations --- end of press release --- About Medigene Medigene AG (FSE: MDG1) is a leading immuno-oncology company dedicated to developing T-cell therapies to effectively eliminate cancer. Its end-to-end technology platform, built on multiple proprietary and exclusive product enhancement and product development technologies, allows Medigene to create best-in-class differentiated, T Cell Receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for both safety and efficacy. This platform provides product candidates for both its in-house therapeutics pipeline and partnering. For more information, please visit www.medigene.com Contacts Medigene AG
Pamela Keck
LifeSci Advisors
Sandya von der Weid
In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.
(Ende)
FOTODIENST
PRESSETEXT.TV
Walter Oblin sieht Post auf Wachstumskurs 18.04.2023 ETARGET
FOCUSTHEMA
SPECIALS
Werbung
middleAdvertising
|